-91%

est. 2Y upside i

HealthcareDevOps & InfraSeed

Open data framework for biology

Rank

#2684

Sector

Biotech, Developer Tools, Data Engineering

Est. Liquidity

~5Y

Data Quality

Data: Low

Lamin offers a high-risk, moderate-upside equity opportunity driven by its specialized open-source data framework for biological R&D, but the job seeker should be aware of the very limited funding and strong incumbent competition in the broader lab informatics space.

Last updated: February 16, 2026

Bull (15%)+400%

Lamin successfully secures substantial follow-on funding, expands its enterprise customer base significantly, and becomes the leading lineage-native lakehouse for biological R&D, leading to a high-multiple acquisition or strong Series B/C.

Base (35%)+50%

Lamin continues to gain traction with its open-source framework and converts some beta customers to paying LaminHub subscribers, but faces ongoing funding challenges and moderate growth, leading to a modest valuation increase or a small acquisition.

Bear (50%)-90%

Lamin struggles to convert open-source adoption into significant revenue, fails to secure sufficient follow-on funding, or is outmaneuvered by better-funded incumbents or new entrants, leading to a pivot, acquisition at a low valuation, or shutdown.

Est. time to liquidity~5.0 years

Community

Valuation Sentiment

Our model estimates -91% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.